Estrigenix Therapeutics, Inc. is a privately held pharmaceutical company developing the next generation of innovative therapies for improving the mental health of menopausal women. Menopause is associated with cognitive dysfunction, increased mood and anxiety disorders, and an elevated risk of Alzheimer’s disease, yet standard estrogen therapies are associated with increased risks of cancer, heart disease, and stroke. Our mission is to develop novel drugs that mitigate the adverse effects of menopause on mental health and enable women to live healthier and happier lives. The drug development program at Estrigenix focuses on selectively activating specific estrogen receptor proteins that promote memory formation, improve mood, and reduce anxiety. We believe that targeting these receptors will provide the cognitive and mood-enhancing benefits of estrogens without the harmful side effects of standard estrogen therapies. Our lead compound, EGX-358, is a potent and selective agonist of the estrogen receptor beta protein, which enhances memory formation in a mouse model of menopause. Current work is expanding the use of this compound to other indications, including depression, anxiety, and hot flashes.
